Efficacy of melatonin to increase cognitive function in depressed patients(Pilot study)

Efficacy of Melatonin to increase cognitive function in depressed patients (pilot study)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20161219004

Enrollment

Unknown

Registered

2016-12-19

Start date

2016-04-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder cognitive function melatomin major depressive disorder

Interventions

melatonin capsule consists of 20 mg oral before bedtime every night,identical capsule oral before bedtime every night

Experimental Drug,Placebo Comparator Drug

melatonin,placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Outpatents with Major depressive disorder according to DSM-5 criteria Age 18-65 years old Stable doses of antidepressants at least 2 months

Exclusion criteria

Exclusion criteria: No any major psychiatric disorder comorbidity No psychotic symptoms No previous treatment with electroconvulsive therapy in last 6 months

Design outcomes

Primary

Measure	Time frame
cognitive function scores baseline, week 4 and week12 ACE-III score/ clinician rate,adverse event baseline, week 4 and week12 self-rated check list/ dichotomous	—

Secondary

Measure	Time frame
Depression symptom score baseline, week4 and week12 HRDS score/ clinician rated,urine 8-isoprostane baseline, week4 and week12 EIA kit/ mg,urine melatonin baseline, week4 and week12 EIA kit/ mg,adverse event baseline, week4 and week12 Adverse effects symptom check list /self-rated .	—

Contacts

Public ContactSuwanna Arunpongpaisal

Khon Kaen University

arunpongsuwanna@gmail.com6643348384

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026